Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.67 |
| ▸ | GSK3A | P49840 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 2/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19558465 | 0.89 | GSK3B (0.62) | GSK3BGSK3ACYP2C19MAPTHTT | |
| SCHEMBL12978293 | 0.84 | HTT (0.83) | CYP2C19MAPTHTTRAB9ANPC1 | |
| SCHEMBL18125241 | 0.83 | NPC1 (0.67) | GSK3BGSK3ACYP2C19MAPTRAB9A | |
| SCHEMBL18125250 | 0.81 | GSK3B (0.65) | GSK3BGSK3AMAPTRAB9ANPC1 | |
| SCHEMBL16710982 | 0.81 | GSK3B (1.00) | GSK3BGSK3AMAPT | |
| SCHEMBL16711009 | 0.80 | MAPT (0.64) | GSK3BGSK3ACYP2C19MAPTBRAF | |
| SCHEMBL18125242 | 0.80 | CYP11B2 (0.60) | GSK3BCYP2C19MAPTHTTRAB9A | |
| SCHEMBL1911526 | 0.80 | HTT (0.67) | CYP2C19HTTRAB9ANPC1LMNA | |
| SCHEMBL19728646 | 0.79 | MAPT (0.57) | GSK3BCYP2C19MAPTRAB9ANPC1 | |
| SCHEMBL16703991 | 0.79 | MAPT (0.79) | GSK3BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809573-B2 | Substituted pyridine derivatives useful as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809573-B2 | Substituted pyridine derivatives useful as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160289210-A1 | Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289210-A1 | Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors | GSK3B, GSK3A, GRIN3A | GSK3B 1/4885GSK3A 2/4885CYP2C19 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.